These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17684496)

  • 41. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease.
    Buizza L; Cenini G; Lanni C; Ferrari-Toninelli G; Prandelli C; Govoni S; Buoso E; Racchi M; Barcikowska M; Styczynska M; Szybinska A; Butterfield DA; Memo M; Uberti D
    PLoS One; 2012; 7(1):e29789. PubMed ID: 22242180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unfolded p53: a potential biomarker for Alzheimer's disease.
    Lanni C; Uberti D; Racchi M; Govoni S; Memo M
    J Alzheimers Dis; 2007 Aug; 12(1):93-9. PubMed ID: 17851197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting.
    Hjelle SM; Sulen A; Øye OK; Jørgensen K; McCormack E; Hollund BE; Gjertsen BT
    J Proteomics; 2012 Dec; 76 Spec No.():69-78. PubMed ID: 22842154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alzheimer's disease: new diagnostic and therapeutic tools.
    Racchi M; Uberti D; Govoni S; Memo M; Lanni C; Vasto S; Candore G; Caruso C; Romeo L; Scapagnini G
    Immun Ageing; 2008 Aug; 5():7. PubMed ID: 18700965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Impaired manifestations of human genetics in pathology and perspectives of improvement in the treatment of diseases of various etiology].
    Paponov VD; Paponov VV; Baĭdakova GV; Borisova AM; Mordovtsev VN
    Ter Arkh; 2004; 76(1):82-7. PubMed ID: 15108447
    [No Abstract]   [Full Text] [Related]  

  • 46. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease.
    Lanni C; Racchi M; Stanga S; Mazzini G; Ranzenigo A; Polotti R; Memo M; Govoni S; Uberti D
    J Alzheimers Dis; 2010; 20(1):97-104. PubMed ID: 20164600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Zyxin is a novel target for β-amyloid peptide: characterization of its role in Alzheimer's pathogenesis.
    Lanni C; Necchi D; Pinto A; Buoso E; Buizza L; Memo M; Uberti D; Govoni S; Racchi M
    J Neurochem; 2013 Jun; 125(5):790-9. PubMed ID: 23330981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Marginalizing the genomic architecture to identify crosstalk across cancer and neurodegeneration.
    Sharma A; Wüllner U; Schmidt-Wolf IGH; Maciaczyk J
    Front Mol Neurosci; 2023; 16():1155177. PubMed ID: 36923654
    [No Abstract]   [Full Text] [Related]  

  • 49. Unfolded p53 in non-neuronal cells supports bacterial etiology of Alzheimer's disease.
    French PW
    Neural Regen Res; 2022 Dec; 17(12):2619-2622. PubMed ID: 35662191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parkin as a Molecular Bridge Linking Alzheimer's and Parkinson's Diseases?
    Checler F; Alves da Costa C
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Trends in Electrochemical Biosensors for Early Diagnosis of Alzheimer's Disease.
    Valkova P; Pohanka M
    Int J Anal Chem; 2021; 2021():9984876. PubMed ID: 34512760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure of prion β-oligomers as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations.
    Serpa JJ; Popov KI; Petrotchenko EV; Dokholyan NV; Borchers CH
    Proteomics; 2021 Nov; 21(21-22):e2000298. PubMed ID: 34482645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?
    Ferri E; Rossi PD; Geraci A; Ciccone S; Cesari M; Arosio B
    Front Mol Biosci; 2020; 7():627931. PubMed ID: 33768114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages.
    Abate G; Vezzoli M; Polito L; Guaita A; Albani D; Marizzoni M; Garrafa E; Marengoni A; Forloni G; Frisoni GB; Cummings JL; Memo M; Uberti D
    J Pers Med; 2020 Dec; 11(1):. PubMed ID: 33375220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer's disease.
    Abate G; Frisoni GB; Bourdon JC; Piccirella S; Memo M; Uberti D
    Alzheimers Res Ther; 2020 Dec; 12(1):160. PubMed ID: 33272326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer's Disease.
    Toyos-Rodríguez C; García-Alonso FJ; de la Escosura-Muñiz A
    Sensors (Basel); 2020 Aug; 20(17):. PubMed ID: 32842632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KLF4 Exerts Sedative Effects in Pentobarbital-Treated Mice.
    Cheng Z; Yang W; Li B; Cui R
    J Mol Neurosci; 2021 Mar; 71(3):596-606. PubMed ID: 32789565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease.
    Farmer KM; Ghag G; Puangmalai N; Montalbano M; Bhatt N; Kayed R
    Acta Neuropathol Commun; 2020 Aug; 8(1):132. PubMed ID: 32778161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular crosstalk between cancer and neurodegenerative diseases.
    Seo J; Park M
    Cell Mol Life Sci; 2020 Jul; 77(14):2659-2680. PubMed ID: 31884567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electrochemical detection of different p53 conformations by using nanostructured surfaces.
    Tonello S; Stradolini F; Abate G; Uberti D; Serpelloni M; Carrara S; Sardini E
    Sci Rep; 2019 Nov; 9(1):17347. PubMed ID: 31758050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.